Makers of a revolutionary cancer treatment asked to slash its 'eye-watering' cost

Nice today announced it was unable to approve a type of CAR-T therapy, called Yescarta, for thousands of non-Hodgkin lymphoma patients on the health service because it is so expensive.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news